Possible correlation between NK-cell development and HCMV infection
| . | p75−KIRS+, % . | p75−NKG2C+, % . | p75−CD56dim, % . | CD56−CD16+, % . | KIRS+NKG2A−, % . | HCMV pp65-antigenemia . |
|---|---|---|---|---|---|---|
| Group 1 | 56 ± 18 | 40 ± 12 | 78 ± 15 | 35 ± 7 | 54 ± 15 | All pts positive |
| Group 2 | 50 ± 17 | 51 ± 15 | 78 ± 14 | 15 ± 5 | 53 ± 18 | All pts positive |
| Group 3 | 5 ± 2 | 3 ± 1 | 14 ± 5 | 7 ± 2 | 13 ± 4 | No pts positive |
| CB | 2 ± 1 | 2 ± 1 | 5 ± 2 | 16 ± 6 | 9 ± 4 | NA |
| Healthy adult | 6 ± 6 | 3 ± 2 | 11 ± 6 | 2 ± 1 | 36 ± 14 | NA |
| . | p75−KIRS+, % . | p75−NKG2C+, % . | p75−CD56dim, % . | CD56−CD16+, % . | KIRS+NKG2A−, % . | HCMV pp65-antigenemia . |
|---|---|---|---|---|---|---|
| Group 1 | 56 ± 18 | 40 ± 12 | 78 ± 15 | 35 ± 7 | 54 ± 15 | All pts positive |
| Group 2 | 50 ± 17 | 51 ± 15 | 78 ± 14 | 15 ± 5 | 53 ± 18 | All pts positive |
| Group 3 | 5 ± 2 | 3 ± 1 | 14 ± 5 | 7 ± 2 | 13 ± 4 | No pts positive |
| CB | 2 ± 1 | 2 ± 1 | 5 ± 2 | 16 ± 6 | 9 ± 4 | NA |
| Healthy adult | 6 ± 6 | 3 ± 2 | 11 ± 6 | 2 ± 1 | 36 ± 14 | NA |
Values are reported as mean ± SD. Data are referred to 6 months after transplantation. All patients from groups 1 and 2 experienced HCMV reactivation, with the exception of patient 9 in whom primary infection occurred.
HCMV indicates human CMV; pts, patients; and NA, not available.